Stephane Poirier, Principal Scientist, Cambridge, USA
Stephane Poirier, Principal Scientist, Cambridge, USA
Fourth Quarter & Full Year 2024 Results
Thursday January 30, 2025 l 15:00 - 16:30 CET (9:00am – 10:30am EST)
Our Latest Stories
Social Impact
February 4, 2025
Childhood Cancer R&D Program: Developing and Accelerating Novel Therapies for Children With Cancer
United by Purpose
Each of us plays a unique role in bringing our purpose to life.
About Us
Who We Are
We are an innovative global healthcare company.
Our Pipeline
5
Therapeutic areas
83
Compounds in clinical development
26
Clinical trials in phase 3
Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Our Latest Press Releases
February 3, 2025
Press Release: Sanofi announces buy back of shares from L’Oréal
January 31, 2025
Press Release: Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
January 30, 2025
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
January 22, 2025
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma